Significantly, napabucasin treatment promoted the infiltration of DCs in tumour tissues, concomitantly increased the expression of antigen presentation‐associated molecules such as CD80, CD86, and MHC II, and the inflammatory cytokines IL‐12 and IFNγ (Fig. 7G), and simultaneously augmented the infiltration of macrophages with upregulation of CD86, IL‐12, IFNγ, and downregulation of PD‐L1 (Fig. 7H). The gene discussed is CD86; the disease is neoplasm.